SFES SAFEGUARD SCIENTIFICS INC
Investors, NEC · OTC · SEC CIK 86115 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (2023Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2023Q4*2023-12-31 | 2023Q3*2023-09-30 | 2023Q2*2023-06-30 | 2023Q1*2023-03-31 | 2022Q4*2022-12-31 | 2022Q3*2022-09-30 | 2022Q2*2022-06-30 | 2022Q1*2022-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $2.00M | $1.31M | $1.19M | $1.19M | $1.03M | $1.36M | $1.15M | $1.23M |
| Operating income | -$2.00M | -$1.31M | -$1.19M | -$1.19M | -$1.03M | -$1.36M | -$1.15M | -$1.23M |
| Pretax income | -$4.41M | $932,000 | -$2.86M | -$3.48M | -$4.87M | -$3.16M | $483,000 | -$6.71M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$4.41M | $932,000 | -$2.86M | -$3.48M | -$4.87M | -$3.16M | $483,000 | -$6.71M |
| EPS (basic) | -0.27 | 0.06 | -0.18 | -0.22 | -0.30 | -0.19 | 0.03 | -0.40 |
| EPS (diluted) | -0.27 | 0.06 | -0.18 | -0.22 | -0.30 | -0.19 | 0.03 | -0.40 |
| Weighted avg. shares (diluted) | — | 16,285 | 16,143 | 16,072 | — | 16,281 | 16,356 | 16,587 |
| Balance sheet | ||||||||
| Cash & equivalents | $9.50M | $15.66M | $14.25M | $11.01M | $13.33M | $15.06M | $17.54M | $19.43M |
| Short-term investments | $0 | $0 | $841,000 | $7.76M | $5.96M | $5.95M | — | — |
| Current assets | $9.91M | $16.28M | $16.73M | $20.14M | $21.42M | $23.81M | $21.07M | $22.90M |
| Total assets | $22.84M | $32.43M | $31.08M | $33.73M | $37.69M | $43.39M | $45.96M | $46.20M |
| Current liabilities | $2.05M | $1.56M | $1.26M | $1.15M | $1.82M | $1.87M | $1.14M | $1.01M |
| Total liabilities | $2.86M | $2.50M | $2.32M | $2.33M | $3.12M | $3.28M | $2.66M | $2.65M |
| Shareholders' equity | $19.98M | $29.93M | $28.76M | $31.39M | $34.58M | $40.11M | $43.30M | $43.55M |
| Shares outstanding | — | 21.57M | 21.57M | 21.57M | 21.57M | 21.57M | 21.57M | 21.57M |
| Cash flow statement | ||||||||
| Operating cash flow | -$818,000 | -$429,000 | -$1.13M | -$928,000 | -$598,000 | -$561,000 | -$1.10M | -$1.00M |
| Investing cash flow | $551,000 | $1.86M | $4.40M | -$1.09M | -$199,000 | -$1.55M | $187,000 | -$3.10M |
| Financing cash flow | -$5.90M | -$20,000 | -$26,000 | -$305,000 | -$905,000 | -$368,000 | -$986,000 | -$1.23M |
| Stock-based compensation | $313,000 | $238,000 | $278,000 | $292,000 | $309,000 | $560,000 | $262,000 | $314,000 |
| Share buybacks | $0 | $0 | $0 | $75,000 | $879,000 | $337,000 | $944,000 | $779,000 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Financial companies (banks, insurers, …) usually do not report gross profit or operating income; bank revenue is net revenue (net interest income + noninterest income), smaller than "gross interest income + noninterest income".
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.